Sprayable gel for postsurgical immunotherapy.
Sprayable gel for postsurgical immunotherapy.
复制标题
DOI：
10.1016/j.iotech.2019.07.001
复制
发表时间：
2019-09
期刊：
影响因子：
--
通讯作者：
Gu, Zhen
中科院分区：
文献类型：
--
作者：
Chen, Qian;Ci, Tianyuan;Gu, Zhen
手术仍然是治疗大多数实体瘤的首选。然而，尽管手术技术不断发展，消除手术后肿瘤复发仍然是一个挑战。在《自然纳米技术》最近发表的一项研究中，我们描述了一种原位喷雾凝胶，用于在手术后将封装有抗 CD47 抗体 (aCD47@CaCO3) 的生物响应和免疫治疗碳酸钙纳米颗粒局部递送到手术部位。 CaCO3 纳米粒子与手术伤口部位的 H+ 发生反应，在手术后引发免疫支持性肿瘤微环境。同时，随后释放的aCD47阻断癌细胞上表达的“别吃我”信号，增加巨噬细胞对癌细胞的吞噬作用，并激活T细胞介导的抗肿瘤免疫反应。这种工程免疫治疗凝胶可以在局部治疗后系统性地激活先天性和适应性免疫反应，有效地破坏剩余的癌细胞并减少肿瘤复发。原位喷涂免疫治疗支架被设计用于方便的术后免疫治疗。设计了原位喷涂免疫治疗支架，以方便术后治疗。调节酸性肿瘤微环境以引发免疫支持反应。对肿瘤进行局部生物反应性免疫治疗可提高疗效并降低毒性。
Surgery remains the first option to treat most solid tumors. However, despite the development of surgical techniques, the elimination of tumor recurrence after surgery remains a challenge. In a recent study published in Nature Nanotechnology, we described an in-situ-sprayed gel for local delivery of bioresponsive and immunotherapeutic calcium carbonate nanoparticles encapsulated with anti-CD47 antibodies (aCD47@CaCO3) to the surgical site after surgery. CaCO3 nanoparticles react with H+ in the surgical wound site, eliciting an immunosupportive tumor microenvironment after surgery. Meanwhile, the subsequently released aCD47 blocks the ‘don’t eat me’ signal expressed on cancer cells to increase the phagocytosis of cancer cells by macrophages and activate T-cell-mediated antitumor immune responses. The engineered immunotherapeutic gel could activate both innate and adaptive immune responses systemically after local treatment, effectively destroying the remaining cancer cells and reducing tumor recurrence. An in-situ-sprayed immunotherapeutic scaffold was engineered for convenient postsurgical immunotherapy. An in-situ-sprayed immunotherapeutic scaffold was engineered for convenient postsurgical treatment. The regulated acidic tumor microenvironment to elicit immunosupportive responses. Local, bioresponsive delivery of immunotherapeutics to tumor improves effect and reduces toxicity.